Introduction
This article serves as a formal correction to the 2018 study published in Nature Communications, which identified recurrent mutations in the USP48 and BRAF genes as significant drivers of Cushing’s disease. Cushing’s disease is characterized by the overproduction of cortisol, typically resulting from ACTH-secreting pituitary adenomas. The original research established that these specific genetic mutations contribute to the pathogenesis of the disease by altering cellular signaling pathways.
The Nature of the Correction
The necessity for this correction arose from a technical error in the assembly of Figure 2b. In the original publication, an immunohistochemistry (IHC) image for BRAF was inadvertently duplicated across two different panels. This update provides the correct IHC images to accurately represent the experimental evidence regarding protein expression and signaling activation in wild-type (WT) versus BRAF V600E-mutated pituitary samples.
Methods and Functional Analysis
The researchers utilized Immunohistochemistry (IHC) to visualize the localization and expression levels of key proteins within tissue sections. The corrected data focuses on three primary markers:
- ACTH: Used to confirm the identity of the hormone-producing cells central to Cushing’s disease.
- BRAF: To visualize the expression of the BRAF protein itself.
- p-Erk1/2: A marker for the phosphorylation (and thus activation) of the MAPK/ERK signaling pathway.
By comparing WT samples with those harboring the BRAF V600E mutation, the study demonstrates the functional consequences of the mutation on downstream signaling.
Key Results: Signaling Activation and Phenotypic Correlation
The corrected Figure 2b provides definitive visual and quantitative evidence of the impact of the BRAF V600E mutation.
Qualitative Observations
While ACTH staining remains consistent across both genotypes—confirming the relevant cell population—the p-Erk1/2 staining reveals a stark contrast. The BRAF V600E mutant samples exhibit significantly more intense and widespread staining for p-Erk1/2 compared to WT samples. This indicates that the mutation actively triggers the MAPK signaling pathway, a known driver of oncogenic growth.
Quantitative Distribution
The accompanying bar chart quantifies these observations across multiple cases. In WT samples, the majority of cases (6 out of 10) show negative (-) p-Erk1/2 staining, with only a small fraction showing high (++) levels. Conversely, in the BRAF V600E cohort, all cases show some level of activation, with the majority (3 out of 5) exhibiting high (++) positivity. This direct correlation between the genotype and the signaling phenotype reinforces the mutation's role as a functional driver of the disease.
Conclusion and Clinical Significance
While the correction addresses a visual assembly error, the fundamental scientific conclusions of the 2018 study remain unchanged. The validation of BRAF V600E as a driver of MAPK activation in Cushing’s disease is particularly significant for therapeutic development. Given that BRAF inhibitors are already successfully employed in treating other BRAF-mutated cancers, such as melanoma, these findings highlight a potential path toward precision medicine for patients with mutation-positive Cushing’s disease.
Summary updated